Skip to main content

Table 2 Relationships between CYP2D6 genotype and clinical outcomes

From: Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone

 

Total study population (n = 76)

CYP2D6*10

CYP2D6*2

CYP2D6*65

Statistics

P

PANSS0 - week 4

19.0 (12.0, 29.0)

24.0 (13.0, 21.0)

10.0 (7.5, 20.8)

5.328

0.070

PANSS0 - week 8

27.5 (19.0, 33.5)

34.5 (31.0, 39.5)

17.0 (13.0, 27.0)

3.850

0.027

BPRS0 – week 4

12.0 (8.0, 15.0)

12.0 (11.0, 13.0)

11.5 (6.3, 13.0)

1.059

0.589

BPRS0 - week 8

16.0 (13.0, 18.5)

15.0 (14.0, 18.0)

14.0(7.0, 17.0)

1.959

0.376

CGI-S0 - week 4

1.0 (1.0, 2.0)

2.0 (1.0, 2.0)

1.0 (1.0, 1.0)

2.853

0.240

CGI-S0 – week 8

2.0 (2.0, 3.0)

3.0 (2.0, 4.0)

2.0 (2.0, 3.0)

1.701

0.427

CGI-I2 – week 4

0.0 (0.0, 1.0)

0.0 (0.0, 0.0)

1.0 (0.0, 1.0)

2.523

0.283

CGI-I2 – week 8

1.0 (0.0, 1.0)

1.0 (0.0, 2.0)

1.0 (0.0, 1.5)

1.249

0.536

  1. Data are presented as median (interquartile range)
  2. PANSS0 - week 4 represents the change of PANSS score from 0 to 4 weeks
  3. Abbreviations: BPRS Brief Psychiatric Rating Scale, CGI Clinical Global Impression, CGI-S Clinical Global Impression Severity, CGI-I Clinical Global Impression Improvement, PANSS Positive and Negative Syndrome Scale
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us